Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Chronic Lymphocytic Leukaemia (CLL): Update Bulletin [November 2017]

Product Code:
596200938
Publication Date:
November 2017
Format:
PDF
Price:
£910

Gain new leading key opinion leader (KOL) insights on the latest events happening in the chronic lymphocytic leukaemia (CLL) space. Topics covered include expert opinions on the results of the Phase III DUO study investigating Verastem’s dual PI3 kinase inhibitor duvelisib in patients with relapsed/refractory CLL. The KOLs also imparted their views on the Phase III MURANO study investigating Venclexta/Venclyxto (venetoclax; AbbVie/Roche) in combination with Rituxan/MabThera (rituximab; Roche), versus bendamustine plus rituximab (BR) in patients with relapsed/refractory CLL. Finally, the experts shared their views on the Phase III CONTINUUM and CLLM1 studies investigating Celgene’s Revlimid (lenalidomide) as a maintenance therapy in CLL.

Business Questions:

• How do KOLs view the results of the DUO study with duvelisib?
• Do the experts anticipate approval of duvelisib for the treatment of CLL?
• What is KOL perception of duvelisib’s safety profile and where do they see this agent fitting into the treatment algorithm?
• How do KOLs anticipate the results of the MURANO study will impact prescribing of venetoclax?
• Do the experts harbour any safety concerns regarding the use of the venetoclax/rituximab combination?
• What are KOL opinions regarding the use of rituximab biosimilars in combination with venetoclax?
• What are KOL expectations for lenalidomide in the treatment of CLL?
• What concerns do the experts have regarding the use of lenalidomide as a maintenance therapy for CLL?
• Do the KOLs anticipate regulatory approval for lenalidomide in CLL?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved